Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-CD19B in Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
NCT02702141Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- Feb 2016
- Primary completion
- Jul 2018
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGN-CD19B in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Seagen Inc. Primary endpoints: Incidence of adverse events and Incidence of laboratory abnormalities. Started Feb 2016; status: terminated.
02
Drugs
SGN-CD19B
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02702141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702141.